Resources>Antibody Industry Trends>Week 4, Apr 2024: Fc-Mediated Functions

Week 4, Apr 2024: Fc-Mediated Functions

Biointron 2024-04-23 Read time: 2 mins
Fc.jpg
Uses of antibody-based biologics. DOI: 10.3389/fimmu.2019.01296

Fc-mediated antibody effector functions play an important role in the humoral immune response and form a necessary link between innate and adaptive immunity. The constant (Fc) region is the tail portion of an antibody that interacts with other components of the immune system, such as immune cells and complement proteins. Well-known functions include opsonization, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement activation. 

During last week’s Fc-Mediated Function Summit, researchers explored various aspects of Fc-mediated functions, such as the pathophysiology of FcRn, targeting FcγR for antibody-based immunotherapy, and innovative drug design with Fc Factor 8. The use of Fc biology was clearly demonstrated to have high potential in advancing molecular development, clinical utility, and novel therapeutic applications. 

A study published this month in Nature explores influenza antibody breadth and effector functions as immune correlates from acquisition of pandemic infection of children. In the study, Jia et al. describes how cross-reactive antibodies with FcR effector functions could lessen pandemic virus impact in the absence of neutralizing antibodies. Their results show that seasonal vaccination is beneficial against pandemic influenza viruses. 

Also related to pandemics, a journal pre-proof by Severa et al. highlights how Fc-mediated regulation of antiviral and inflammatory responses, in absence of viral replication, might positively tune immune response during SARS-CoV-2 infection. It may also be exploited in monoclonal antibody-based therapeutic and prophylactic strategies against viral infections.

Recommended Articles
Biointron Insights: Antibody Industry Trends (Q3 2026 Insights, Trends & Analysis)

Biointron's Q3 2026 Antibody Industry Trends report aims to explore the events a……

Sep 30, 2026
September 2026: Wet Lab Data Generation for AI-Driven Antibody Discovery

Artificial intelligence (AI) can be used throughout the drug development process……

Sep 09, 2026
Week 1, September 2026: Engineering Peptides into Antibodies: Recent Directions in Therapeutic Design

Peptides and antibodies have different strengths as therapeutic molecules. Pepti……

Sep 02, 2026
Week 3, August 2026: Targeting Pathological Protein Aggregates with Antibodies

Therapeutic antibodies are often used to block receptors or neutralize soluble m……

Aug 26, 2026

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.